Literature DB >> 2573506

Rational use of antihistamines in allergic dermatological conditions.

C Advenier1, C Queille-Roussel.   

Abstract

For many years, the use of antihistamines in dermatological conditions has been closely linked to the treatment of urticarias and to the symptomatic relief of pruritus. H1-receptor antagonists are the first-line drugs for urticarias. Those urticarias of type I immunological origin respond better than physical urticarias. H2-receptor antagonists may be added for refractory patients but are rarely effective alone. Conventional H1-blockers are frequently associated with somnolence and anticholinergic effects. Therefore, new antihistamines without depressive effects on the central nervous system have recently been introduced. In other pruritic conditions such as atopic dermatitis the limited effects of these drugs suggest that histamine is not the only mediator involved in pruritus. In these cases, their beneficial effects seem to be due mainly to their sedative properties; recently available nonsedative H1-blockers are less effective.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573506     DOI: 10.2165/00003495-198938040-00009

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  46 in total

1.  Evidence for non-mast cell histamine in the vascular wall.

Authors:  T M El-Ackad; M J Brody
Journal:  Blood Vessels       Date:  1975

2.  Cimetidine-induced remission of mycosis fungoides.

Authors:  S W Mamus; J Mladenovic; M K Hordinsky; M V Dahl; N E Kay
Journal:  Lancet       Date:  1984-08-18       Impact factor: 79.321

Review 3.  H1 receptor antagonist treatment of chronic rhinitis.

Authors:  F E Simons; K J Simons
Journal:  J Allergy Clin Immunol       Date:  1988-05       Impact factor: 10.793

4.  The effect of terfenadine on dermographic wealing.

Authors:  L B Krause; S Shuster
Journal:  Br J Dermatol       Date:  1984-01       Impact factor: 9.302

Review 5.  Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines).

Authors:  D M Paton; D R Webster
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

6.  Terfenadine does not inhibit non-immunologic contact urticaria.

Authors:  A Lahti
Journal:  Contact Dermatitis       Date:  1987-04       Impact factor: 6.600

7.  Urinary excretion of histamine, methylhistamine (1-MeHi) and methylimidazoleacetic acid (MeImAA) in mastocytosis: comparison of new HPLC methods with other present methods.

Authors:  G Granerus; U Wass
Journal:  Agents Actions       Date:  1984-04

8.  Cutaneous histamine levels and histamine releasability from the skin in atopic dermatitis and hyper-IgE-syndrome.

Authors:  T Ruzicka; S Glück
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

9.  Mast cell population density, blood vessel density and histamine content in normal human skin.

Authors:  R A Eady; T Cowen; T F Marshall; V Plummer; M W Greaves
Journal:  Br J Dermatol       Date:  1979-06       Impact factor: 9.302

Review 10.  Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  S P Clissold; E M Sorkin; K L Goa
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

View more
  3 in total

Review 1.  Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines.

Authors:  J P Desager; Y Horsmans
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

2.  Influence of histamine receptor antagonists on the dynamics of the cutaneous hypersensitivity reaction in patients infected with schistosoma haematobium.

Authors:  J R Snyman; D K Sommers; M D Gregorowski
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  Public health problems and the rapid estimation of the size of the population at risk. Torsades de pointes and the use of terfenadine and astemizole in The Netherlands.

Authors:  R M Herings; B H Stricker; H G Leufkens; A Bakker; F Sturmans; J Urquhart
Journal:  Pharm World Sci       Date:  1993-10-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.